Background--The optimal initial noninvasive diagnostic testing strategy for stable coronary artery disease (CAD) is unknown. Although American guidelines recommend an exercise stress test as the first-line test, European guidelines suggest that stress imaging (myocardial perfusion imaging or stress echocardiography) or coronary computed tomography angiography may be preferable. Understanding the relationship between the initial strategy and downstream yield of obstructive CAD and major adverse cardiac events may provide insight as to the optimal strategy.
T here are currently 4 cardiac noninvasive diagnostic tests for identifying coronary artery disease (CAD) that are clinically available and reimbursed in Ontario, Canada: graded exercise stress test (GXT), myocardial perfusion imaging (MPI), coronary computed tomography angiography (CCTA), and stress echocardiography (stress echo). There is disagreement between American and European guidelines with respect to which test should be initially used for the evaluation of patients with stable CAD (SCAD). Although the American guidelines recommend GXT as the first-line test when it is possible to perform, the European guidelines suggest that stress imaging tests or CCTA may be a preferable initial approach in certain patient groups. [1] [2] [3] Furthermore, although many studies have assessed the clinical efficacy of these tests in selected populations, none have assessed the comparative clinical effectiveness of these modalities in a head-to-head fashion in a population-based study. With healthcare budgets rising sharply in many highincome countries and with cardiac diagnostic testing and medical imaging contributing substantively to these costs, the assessment of comparative clinical effectiveness is important to assess the real-world impact of these modalities.
The ideal outcome measure to assess the clinical effectiveness of cardiac noninvasive diagnostic tests is not currently established. The yield of obstructive CAD based on downstream invasive angiography has recently been used as an outcome measure in studies designed to assess the clinical effectiveness of noninvasive cardiac diagnostic tests. [8] [9] [10] Recent registry data suggest that only %38% of those referred for invasive angiography in the United States for the diagnosis of SCAD had obstructive CAD on invasive angiography. 11, 12 Consequently, understanding the relationship between the initial noninvasive cardiac diagnostic tests and subsequent downstream yield of obstructive CAD may provide insight as to which noninvasive test to use, thereby reducing unnecessary invasive angiograms and the resultant complications. The objective of this study was to determine whether a diagnostic strategy with an initial MPI, stress echo, or CCTA was independently predictive of a higher yield of obstructive CAD compared with GXT, after adjusting for clinically relevant covariates. To provide another metric of effectiveness, we also assessed a composite end point of major adverse cardiac events (MACE). Based on studies showing greater clinical efficacy, we hypothesized that a strategy with initial MPI, stress echo, or CCTA would lead to a higher yield of obstructive CAD compared with a strategy using initial GXT.
Methods Design
We conducted a retrospective cohort study of patients undergoing an initial test in the calendar year 2012.
Derivation of the Cohort
Patients began entering the cohort on January 1, 2012 (see Figure 1 ). Inclusion criteria were age ≥20 years; receipt of 1 GXT, stress echo, CCTA, or MPI; and receipt of invasive angiography for the evaluation of SCAD. The first cardiac noninvasive diagnostic test after January 1, 2012, for each patient was deemed the index event or test. Index tests were identified between January 1, 2012, and December 31, 2012.
Index events begin (Jan 1, 2012)
ObservaƟon Window for receipt of invasive angiography (Jan 1, 2012-June 30, 2013) June 30, 2013 Look-back Window to exclude prior CAD (Jan 1, 1992) Figure 1 . Schematic representation of the design of the cohort study. This figure demonstrates the design of our study and outlines the observation window, follow-up period, and look-back window for our study. CAD indicates coronary artery disease; MACE, major adverse cardiovascular events.
Clinical Perspective
What Is New?
• The optimal initial noninvasive diagnostic testing strategy for stable coronary artery disease is unknown.
• Population-based real-world data comparing outcomes related to different initial strategies are scarce.
• There is disagreement between American and European guidelines with regard to the optimal initial strategy.
• Our population-based retrospective cohort study of adults in Ontario, Canada (approximate population: 10.1 million), found no significant differences in either yield of obstructive coronary artery disease or downstream major adverse cardiovascular events in patients undergoing an initial noninvasive testing strategy with stress or anatomical imaging compared with those undergoing an initial simple exercise stress test.
What Are the Clinical Implications?
• Our results do not support the routine initial use of stress imaging or coronary computed tomography angiography in the workup of stable coronary artery disease.
• These findings highlight the need for future research to explore the reasons for the discrepancy between our realworld findings and those of clinical efficacy studies.
We used a look-back window of 20 years (back to January 1, 1992) to exclude patients with prior cardiovascular disease. Previous cardiovascular disease was defined by prior hospitalization for acute myocardial infarction, stroke, congestive heart failure, percutaneous coronary intervention, and coronary artery bypass grafting, using previously validated algorithms. [13] [14] [15] [16] [17] [18] [19] We also used a 1-year washout period such that patients who had 1 of the 4 noninvasive diagnostic tests during the 2011 calendar year were excluded. After the index event, patients were followed for a maximum of 6 months to identify whether they progressed to invasive angiography. Consequently, the observation window for invasive angiography was from January 1, 2012, to June 30, 2013 , to provide a full 6 months of follow-up for the last potential person entering the cohort on December 31, 2012. Furthermore, patients were followed for a maximum of 2 years after their invasive angiogram (until June 30, 2015) to ascertain MACE. 24, 25 All data were accessed and analyzed at ICES in Toronto, Canada. ICES has been deemed a prescribed entity by the government of Ontario. This status allows it to collect personal information without the need for informed consent; therefore, approved projects using ICES data, such as this one, are exempt from the requirement of informed consent.
Data Sources

Exposure
The exposure was the receipt of 1 of the 4 index noninvasive tests.
Outcomes
In those patients who underwent angiography for the assessment of SCAD, we determined whether their angiogram showed obstructive CAD, our primary outcome of interest. Obstructive CAD on angiography was defined as stenosis of ≥50% of the left main coronary artery or ≥70% of a major epicardial or branch vessel, according to CCN data in a manner previously described and validated. 25, 26 Furthermore, as a secondary outcome, patients were followed after their invasive angiogram for the development of MACE, defined as a composite end point of all-cause mortality and hospitalization for acute myocardial infarction or unstable angina.
Covariates
Covariates for inclusion in multivariable models were selected a priori based on clinical importance. We used the demographic information in Table 1 to calculate this score. Each patient was assigned a total score based on the sum of scores for sex-based age, dyslipidemia, hypertension, smoking, and diabetes mellitus.
initial testing strategies using the v 2 test for categorical variables and analysis of variance for continuous variables.
Logistic regression analyses
Unadjusted analyses. Unadjusted analyses were performed using logistic regression models to assess the relationship of the index cardiac noninvasive tests with downstream obstructive CAD in those patients who underwent invasive angiography for the evaluation of SCAD. GXT was considered the reference test.
Adjusted analyses. We performed multivariable logistic regression analyses to examine the association between the index noninvasive cardiac diagnostic tests and downstream obstructive CAD in those patients who underwent angiography for the evaluation of SCAD, controlling for the clinical covariates listed earlier. Before performing the logistic regression analyses, all predictor variables were assessed for the presence of multicollinearity. We concluded that there was no significant multicollinearity among the predictor variables included in the models based on the fact that none of the variables had a variance inflation factor >4 or tolerance <0.25. Subsequently, subgroup analyses were performed for those at high, intermediate, and low modified Framingham risk scores.
Time-to-event analyses for MACE. We compared time to event (development of MACE) using Kaplan-Meier survival curves estimated for each of the 4 noninvasive test groups. These were compared across the 4 test groups using the logrank test. Subsequently, we utilized a Cox proportional hazards model to adjust for clinical covariates. We obtained direct adjusted or marginal survival curves by noninvasive test group using previously described methods. 41, 42 We subsequently performed subgroup analyses for those at high, intermediate, and low modified Framingham risk scores.
A 2-tailed value of P<0.05 was considered statistically significant. Analyses were performed with SAS version 9.3. This study was approved by the research ethics board at Sunnybrook Health Sciences Center.
Results
Cohort Creation
In 2012 in Ontario, 464 647 patients aged ≥20 years had GXT, MPI, stress echo, or CCTA. Of these, 45 711 were excluded for having 1 of the 4 cardiac noninvasive diagnostic tests in the preceding 12 months. An additional 69 443 patients were excluded for having a previous diagnosis of cardiovascular disease in the preceding 20 years. Of the remaining 349 493 patients, a total of 18 819 underwent subsequent invasive angiography. The final cohort consisted of 15 467 patients who underwent invasive angiography for the indication of SCAD (see Figure 2 ).
Progression to Angiography Among Patients With Various Initial Noninvasive Tests
Of the 349 493 patients who had a noninvasive cardiac diagnostic test in 2012 in Ontario, 1748 patients underwent initial CCTA, 175 900 underwent initial GXT, 128 622 underwent initial MPI, and 43 223 underwent initial stress echo. Within our observation period, 113 (6.5%) of those with initial CCTA versus 6877 (5.3%) with initial MPI, 1735 (4.0%) with initial stress echo, and 6742 (3.8%) with initial GXT received invasive angiography for the diagnosis of SCAD (P<0.001). Table 3 and Figure 3 ). 
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Subgroup analyses
Major Adverse Cardiac Events
Patients were followed for a mean time of 1.89 years (SD: 0.42 year) after coronary angiography. Overall, 833 (5.4%) developed the composite end point during the follow-up period. This included 9 patients with initial CCTA (7.9%), 358 with initial GXT (5.3%), 395 with initial MPI (5.7%), and 71 with initial stress echo (4.1%). In the unadjusted model, those undergoing angiography with an index CCTA or MPI had a higher risk of developing the composite outcome than those with an initial GXT or stress echo (log-rank P=0.03); however, after adjustment for clinical covariates, there was no significant difference in MACE among the 4 initial testing strategies (see Figure 5 ). In the adjusted stratified analysis, those in the low-risk subgroup with an initial CCTA had a borderline significant increased risk of developing the composite outcome, whereas those with an initial MPI or stress echo had no significant difference in terms of risk of developing the composite outcome compared with those who had an initial GXT. There were no significant differences in terms of risk of developing the composite outcome between the initial testing strategies in the intermediate-and low-risk subgroups after adjustment for relevant clinical covariates (see Figure 6 ).
Discussion
The most common initial noninvasive test in our cohort was MPI. The prevalence of most major cardiovascular risk factors was higher in those with initial MPI compared with patients whose initial test was CCTA, stress echo, or GXT. Patients whose initial test was MPI tended to have a higher mean Charlson comorbidity index score. They also were more likely to have a higher modified Framingham risk score. Those with an index CCTA were most likely to be female and to have CCS class 3 to 4 symptoms. After adjusting for relevant covariates, patients with an initial testing strategy with MPI, CCTA or stress echo did not have a statistically significant different yield of obstructive CAD compared with patients with an initial testing strategy using a GXT. Furthermore, there was no significant difference in downstream rates of MACE among the 4 initial testing strategies.
Noninvasive Diagnostic Tests to Diagnose CAD
The optimal strategy to evaluate patients with suspected SCAD is currently uncertain. The recent proliferation of noninvasive cardiac diagnostic testing technology has led to various potential options for the noninvasive diagnosis of CAD. among the different index cardiac noninvasive diagnostic testing strategies. Multivariable model displaying the odds ratios and 95% confidence intervals of the yield of obstructive CAD among the different index cardiac noninvasive diagnostic tests in patients who underwent invasive angiography for the assessment of stable CAD (GXT is the reference test). Adjusted for age, sex, presence of diabetes mellitus, dyslipidemia, hypertension, income quintile, resting ECG abnormalities, Charlson comorbidity index score, serum creatinine, smoking history, Canadian Cardiovascular Society class angina symptom scale, chronic obstructive pulmonary disease, peripheral vascular disease, and modified Framingham risk score. CCTA indicates coronary computed tomography angiography; CI, confidence interval; GXT, graded exercise stress test; MPI, myocardial perfusion imaging; OR, odds ratio; stress echo, stress echocardiogram. who are able to exercise in the absence of significant ST-T wave abnormalities. 3 In contrast, the 2013 and 2014 European Society for Cardiology (ESC) guidelines on SCAD and revascularization are more liberal in their recommendations of stress and anatomic imaging as the initial testing strategy. Class 1 recommendations in the ESC documents are conferred to stress imaging when there are baseline ECG abnormalities, when patients are unable to exercise, and when stress imaging is available and there is local expertise. Furthermore, there is a class 1 recommendation for stress imaging for high-risk patients and a class IIa indication for CCTA in the diagnosis of SCAD.
1,2
Many studies have examined the efficacy of CCTA, GXT, MPI, and stress echo in selected populations [43] [44] [45] ; however, despite widespread clinical adoption of newer technologies, there have been limited data comparing their relative clinical effectiveness, specifically by comparing their real-world downstream outcomes. 4, 5 The lack of a clear demonstration of an effect on outcomes has led to calls for regulation aimed at controlling spending and improving quality. 46, 47 Little comparative effectiveness research has been published on differing initial noninvasive diagnostic strategies that are currently available to clinicians.
Yield of Obstructive CAD
The optimal end point to assess clinical effectiveness is currently unknown. In recent years, the concept of yield of obstructive CAD has emerged as a surrogate end point designed to assess the clinical effectiveness of cardiac diagnostic tests. Multiple studies have linked obstructive CAD to an increase in mortality. 3, 48, 49 Recent registry data reported
Low risk Intermediate risk
High risk an obstructive CAD rate of only 37.6% on invasive angiograms of patients being evaluated for SCAD. 11 Given the potential risks associated with invasive angiography, it is important to assess the yield of obstructive CAD related to cardiac noninvasive diagnostic tests. The PROMISE trial reported that although more patients underwent catheterization, there were significantly fewer diagnostic angiograms showing nonobstructive CAD in the anatomic versus the functional groups. 47 The yield of obstructive CAD was 72.1% in the anatomic group versus 47.5% in the functional group (P=0.02). 47 Another recent study retrospectively collected data on 209 patients evaluated at chest pain clinics at 2 British hospitals. The first hospital evaluated patients with a strategy of GXT as the first and only cardiac noninvasive diagnostic test. The second used a "cardiac imaging" pathway that involved a combination of coronary artery calcium score, CCTA, MPI, and stress echo. They concluded that the cardiac imaging strategy resulted in fewer invasive angiograms and a higher yield of obstructive CAD. 10 They did not analyze the yield of obstructive CAD among the different testing modalities in the imaging arm.
Major Adverse Cardiac Events
The relationship between a diagnostic imaging test and downstream "hard" cardiovascular outcomes such as mortality and nonfatal cardiovascular events is complex. Clinical decisions made after the imaging test have a significant impact on the development of such outcomes. Nonetheless, when comparing the clinical effectiveness of different diagnostic testing modalities, a recent position paper recommended examining such outcomes with the recognition that they are a reflection of the strategy and the entire diagnostic/therapeutic pathway initiated by a test rather than a reflection of the efficacy of the test itself with isolation of other downstream factors. 4 This study, to our knowledge, is the first analysis to directly compare the yield of obstructive CAD and MACE based on strategies of initiation of the diagnostic pathway for SCAD with either a GXT, MPI, stress echo, or CCTA at the level of the entire adult population; therefore, we were able to assess the potential real-world impact of the initial noninvasive testing strategies in the largest province in Canada (approximate adult population of 10.1 million). Our results indicate that an initial diagnostic strategy with MPI, CCTA, or stress echo did not result in a higher yield of obstructive CAD or differential downstream MACE compared with a GXT. The exception may be in the low-risk CCTA group, for which our subgroup analysis indicated that those who had an initial CCTA were more likely to have obstructive CAD on downstream angiography compared with those with an initial GXT. This result needs to be interpreted with caution because it was the result of a post hoc subgroup analysis, and the level of statistical significance was borderline (P=0.047).
Another important finding in our study was that CCTAs were more likely to be performed in higher income individuals. This phenomenon is similar to trends observed in utilization of other diagnostic tests including magnetic resonance imaging in Ontario. [50] [51] [52] [53] Higher income individuals may be more aware of emerging and new technologies and may be more likely to ask their physicians to order a newer modality such as CCTA.
37,51,54
Significance
We expected that an initial diagnostic strategy with MPI, stress echo, or CCTA would have a significantly higher yield of obstructive CAD compared with a GXT. Our hypothesis was based on clinical efficacy studies showing superior accuracy of the former 3 modalities compared with GXT. Our results failed to support our hypothesis. Instead, our results showed that in a large contemporary real-world population-based cohort in Ontario, Canada, an initial noninvasive diagnostic strategy with a CCTA, stress echo, or MPI failed to result in a higher yield of obstructive CAD compared with an initial strategy with a GXT. Furthermore, there was no significant difference in downstream MACE between the different initial testing strategies. Consequently, within the context of the limitations of our study, our results do not support the routine initial use of stress imaging or CCTA in the workup of SCAD. These findings highlight the need for future research to explore the reasons for the discrepancy between our realworld findings and those of clinical efficacy studies.
Limitations
Our study must be interpreted in the context of a number of limitations. First, we had limited access to granular clinical data; for example, we were able to detect whether or not a patient had a noninvasive test, but we did not have access to the result of that test. We assumed that those who were not referred for angiography had negative noninvasive tests. Second, our analysis focused on the yield of obstructive CAD. By its nature, it included only patients who underwent invasive angiography. We did not assess the patients whose diagnostic cascade was appropriately terminated with a negative noninvasive test. positron emission tomography nuclear imaging because of the absence of an associated physician billing code and/or limited clinical availability. Fifth, the number of patients who underwent angiography after having an index CCTA was small. Consequently, we were likely underpowered to show a statistically significant difference in yield of obstructive CAD compared with GXT. Finally, although we attempted to adjust for all known relevant confounders, the observational nature of this study raises the possibility of the presence of unknown confounders that may have inadvertently affected our results.
Conclusions
Our study found no evidence to suggest a higher yield of obstructive CAD with an initial testing strategy with stress imaging or CCTA compared with GXT. Furthermore, we found no evidence of improvements in downstream MACE with either a stress imaging or CCTA initial testing strategy compared with an initial GXT. These real-world results, therefore, do not provide evidence to support the routine initial use of stress imaging or CCTA in the workup of SCAD.
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